SCHEMBL2996096

SCHEMBL2996096

CC1(C)CNC(=O)c2[nH]c3ccc(C(=O)O)cc3c21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 5/20 0.64
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
THRB P10828 1/20 0.46
HPGD P15428 1/20 0.46
GSK3B P49841 3/20 0.45
CCNB2 O95067 1/20 0.45
CDK1 P06493 1/20 0.45
CCNB1 P14635 1/20 0.45
CCNB3 Q8WWL7 1/20 0.45
CDK5 Q00535 2/20 0.44
GSK3A P49840 1/20 0.44
CDK5R1 Q15078 1/20 0.44
PPARG P37231 1/20 0.43
PLK4 O00444 1/20 0.41
DAPK3 O43293 1/20 0.41
DYRK3 O43781 1/20 0.41
JAK2 O60674 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002604 0.86 MAPKAPK2 (0.67) MAPKAPK2KDM4EALDH1A1HPGDGSK3B
SCHEMBL13248584 0.82 MAPKAPK2 (0.64) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL14730689 0.81 KDM4E (0.47) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL13248414 0.80 MAPKAPK2 (0.63) MAPKAPK2
SCHEMBL3005560 0.80 KDM4E (0.46) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL3004600 0.78 MAPKAPK2 (0.65) MAPKAPK2ALDH1A1MAPK1KMT2APOLB
SCHEMBL2991108 0.78 MAPKAPK2 (0.66) MAPKAPK2MAPK1
SCHEMBL14730748 0.78 KDM4E (0.44) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL14731426 0.77 KDM4E (0.43) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL14731413 0.73 MAPKAPK2 (0.50) MAPKAPK2KDM4EALDH1A1HPGDGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US claimed
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US claimed
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US disclosed
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US disclosed
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US disclosed
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 MAPKAPK2 1/4885KDM4E 2943/4885ALDH1A1 3894/4885
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 MAPKAPK2 1/4885KDM4E 2943/4885ALDH1A1 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.